Interestingly, Trastuzumab-resistant HBCx-5 tumor is characterized by reduced miR-205, higher HER3 and p-AKT levels compared to Trastuzumab-sensitive HBCx-13B and T226 tumors (Figure 3B, 3C), further supporting the idea that loss of miR-205 and the consequent upregulation of its target HER3 are associated to reduced response. Here, ERBB3 is linked to neoplasm.